Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Authorized symbols : SRNE save search
FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain
Published: 2021-10-13 (Crawled : 13:15) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 2.45%
H: 0.52%
C: -0.15%
fda phase 2 cancer trial authorized
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 1.71%
H: 1.8%
C: -0.12%
fda phase 1 therapy trial authorized t-cell
Sorrento Receives EUA Approval and Import License From Mexico Authority COFEPRIS For COVI-STIX™ (COVID-19 Virus Rapid Antigen Detection Test) and Plans Product Launch With Initial Shipments in July
Published: 2021-06-24 (Crawled : 18:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.44%
H: 11.34%
C: 10.13%
covid test license approval authorized
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
Published: 2021-06-11 (Crawled : 21:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
| Email alert
Add to watchlist
phase 2 drop trial authorized
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
Published: 2021-05-20 (Crawled : 13:15) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 1.43%
H: 4.24%
C: 1.98%
covid phase 2 brazil respiratory trial authorized syndros
Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX™ Rapid Detection Test of SARS-CoV-2 Viral Antigen
Published: 2020-12-30 (Crawled : 18:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.73%
H: 5.49%
C: 4.55%
test submission authorized sars-cov-2
Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen
Published: 2020-12-22 (Crawled : 00:02) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 6.51%
H: 15.47%
C: 11.31%
fda merge test authorized sars-cov-2 application emergency use authorization
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
ZCMD | $2.44 78.1% 43.85% 330K
|
Commercial Services
XPON | $3.1 60.62% 37.74% 16M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
PRTG | $0.299 35.17% 120K
|
Mining, Quarrying, and Oil and ...
Your saved searches
Save your searches and get alerts when important news are released.